Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumour burden and portal vein tumour thrombus (CHANCE 2416): study protocol of a multicentre, retrospective, target trial emulation design.

ABSTRACT:

Background

Advanced-stage hepatocellular carcinoma (HCC) with high tumour burden and portal vein tumour thrombus (PVTT) is usually associated with poor survival outcomes. Rapid tumour control usually benefits long-term outcomes, which could be hardly achieved by solely systematic targeted and immunotherapy in current guidelines. Hepatic arterial infusion chemotherapy (HAIC) is reported as an effective intervention for rapid decrease of tumour burden. In order to determine the role of HAIC in the comprehensive treatments, a target trial emulation study is conducted to compare the effectiveness and safety of HAIC in combination with lenvatinib and programmed death receptor-1 (PD-1) inhibitors (H+L+P) to that of lenvatinib and PD-1 inhibitors (L+P) in patients with advanced HCC exhibi

SUBMITTER: Liu J 

PROVIDER: S-EPMC12421617 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature